Astellas Pharma to invest $50m in Poseida to advance cancer cell therapy
According to the terms of the agreement, Astellas will invest $25m to buy 8,333,333 shares of common stock…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Aug 23
According to the terms of the agreement, Astellas will invest $25m to buy 8,333,333 shares of common stock…
08 Aug 23
Under the terms of the agreement, Nautic will acquire Tabula Rasa for $10.50 in cash per share and…
PharmaceuticalsConsulting, Training and Other Pharmaceutical Services
08 Aug 23
The patent is backed by vast nonclinical data and early clinical data that point to the potential for…
08 Aug 23
The Alinity h-series system includes an integrated slide maker and stainer Alinity hs, and an automated haematology analyser…
08 Aug 23
IPAX-2 is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with external…
08 Aug 23
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a…
08 Aug 23
NS-089/NCNP-02 previously received Rare Pediatric Disease Designation from the FDA in June 2023 and Breakthrough Therapy Designation in…
08 Aug 23
The FDA approval expands the use of QuikClot Control+ haemostatic device to include mild and moderate bleeding in…
08 Aug 23
According to the company, Masimo PSi, which is a SedLine parameter from electroencephalographic data, was found statistically and…
07 Aug 23
Zurzuvae causes central nervous system (CNS) depressant effects, and people who take the drug should not drive a…